NCT00786838View on ClinicalTrials.gov

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Solid Tumor
Interventions
DRUG

Trabectedin

Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.

DRUG

Placebo

Participants will receive 3-hour placebo intravenous infusion on Day 1.

Trial Locations (17)

Unknown

Miami

Charlotte

Philadelphia

Tacoma

Brussels

Edegem

Wilrijk

Lyon

Marseille

Montpellier

Villejuif

Bengaluru

Pune

Moscow

Saint Petersburg

Seoul

PAU de Sanchinarro

Sponsors

Collaborators (1)

PharmaMar
All Listed Sponsors
collaborator

PharmaMar

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00786838 - A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram | Biotech Hunter | Biotech Hunter